Post Profile

Bristol-Myers to pay $1.85 billion in cancer deal with Nektar

(Reuters) - Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion in cash and share purchase for a global development and commercialization deal on a promising Nektar cancer drug, the companies announced on Wednesday.
read more


Related Posts

EMA panel recommends against Nektar, Daiichi Sankyo's breast cancer drug

Health : Reuters: Health

(Reuters) - European regulators on Friday recommended against granting approval to a breast cancer drug being developed by Nektar Therapeutics and Daiichi Sankyo's German unit.

Pharma giant Bristol-Myers Squibb just made another huge bet on cancer immunotherapy (BMY)

Business & Finance : Business Insider: Clusterstock

Bristol-Myers Squibb, a company known for its cancer immunotherapy drugs, just acquired immunotherapy startup IFM Therapeutics. The deal is worth $300 million upfront, and if IFM's two drug programs hit certain development milestone...

Japan sets 50 percent price cut for Bristol Myers' Opdivo cancer drug

Health : Reuters: Health

(Reuters) - Japan's health ministry has set a 50 percent cut in the price of Opdivo, a costly immune system-boosting cancer drug produced by Bristol Myers Squibb Co and marketed in the country by Ono Pharmaceutical Co Ltd, Ono Pharm...

Bristol-Myers to test Opdivo with Nektar drug for several cancers

Health : Reuters: Health

(Reuters) - Bristol-Myers Squibb Co said on Tuesday it would evaluate the use of its blockbuster cancer immunotherapy Opdivo in combination with an experimental drug from Nektar Therapeutics to treat multiple cancers.

Why Bristol Myers is Paying the Biggest Pharma Premium of 2009.

Business & Finance : Deal Journal -

In the world of biotech M&A, it's not about the science. It's about the gamble. Consider the case of Medarex Inc., a maker of a promising a cancer drug, which agreed to by acquired by Bristol Myers Squibb Co. for $2.4 billion


Copyright © 2016 Regator, LLC